Yes. Imdur tablets can be carried in your hand luggage. Keep them in the original pharmacy-labelled container and have a copy of the prescription or a medication summary in case security requests verification.
A mild headache is common and often improves with continued therapy. If the headache is severe or persistent, contact your prescriber; they may recommend a temporary dose reduction or an analgesic that does not interfere with nitrate metabolism.
Nitrates can occasionally cause blurred vision or increased light sensitivity, especially in patients with pre-existing eye conditions. Report any sudden visual disturbances to a healthcare professional promptly.
Both are organic nitrates, but isosorbide mononitrate (Imdur) has a longer half-life and more stable plasma concentrations, allowing once-daily dosing, whereas isosorbide dinitrate often requires multiple daily doses.
Yes, but the combination may amplify blood-pressure lowering effects. Your doctor will monitor your blood pressure and may adjust one or both agents to avoid excessive hypotension.
The first-dose phenomenon describes sudden drops in blood pressure and pronounced headache when starting a nitrate. Starting with the lowest dose (20 mg) taken in the morning and slowly titrating reduces this risk.
Imdur tablets contain lactose, maize starch, and magnesium stearate among other excipients. Patients with lactose intolerance or severe corn allergies should discuss alternatives with their clinician.
Nitrates do not typically interfere with standard laboratory assays. However, they may slightly elevate methemoglobin levels; routine blood counts remain unaffected.
Both contain the same active ingredient, but Imdur is a branded extended-release product with specific release characteristics. If you consider switching, ensure your doctor reviews the dosing schedule to maintain therapeutic consistency.
Imdur is listed on the NHS Drug Tariff and may be prescribed at standard rates. Coverage depends on the individual’s prescription details and local NHS policies.
Imdur is a prescription-only pill marketed in the United Kingdom for the prevention of angina pectoris. Its active ingredient is isosorbide mononitrate, a member of the organic nitrate class that belongs to the broader “Heart & Blood Pressure” therapeutic category. Imdur is available in 20 mg, 30 mg, 40 mg, and 60 mg extended-release tablets. The medication is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) and is listed in the British National Formulary (BNF) for chronic angina management.
Isosorbide mononitrate is a nitrate donor. After oral ingestion, it is absorbed and converted to nitric oxide (NO) within vascular smooth muscle. NO activates guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP). Elevated cGMP leads to relaxation of smooth muscle, producing vasodilation of both veins and arteries.
The net effect is a reduction in myocardial oxygen demand, which helps prevent angina attacks. The drug’s onset of action is typically within 30 minutes, with a peak effect around 2-4 hours and a duration of 12-24 hours, allowing once-daily dosing.
Imdur is approved in the UK for the prophylactic treatment of stable angina pectoris in adults. It is not indicated for relief of acute angina episodes; patients should have a fast-acting nitroglycerin formulation for breakthrough pain.
Evidence from small trials and observational studies has explored the use of isosorbide mononitrate in heart failure with reduced ejection fraction (HFrEF) and hypertension. These uses are not approved by the MHRA and should only be considered under specialist supervision.
Disclaimer: Off-label use requires individualized risk assessment and close monitoring by a qualified healthcare professional.
Standard dosing:
Start with 20 mg once daily (or the lowest available strength) taken in the morning.
After 1-2 weeks, the dose may be increased to 30 mg, 40 mg, or 60 mg once daily based on symptom control and tolerability.
The maximum recommended dose is 60 mg per day.
Titration strategy: Gradual increase minimizes the “first-dose” phenomenon (pronounced hypotension and headache after the initial dose).
Special populations:
Elderly: Begin at the lowest dose; monitor blood pressure and renal function.
Renal/hepatic impairment: No routine dose reduction required for mild-to-moderate disease; severe dysfunction may need individualized adjustment.
Pediatric use: Not approved.
Administration: Swallow the extended-release tablet whole; do not crush, chew, or split it, as this can release the full dose rapidly and increase the risk of hypotension.
Missed dose: If a dose is missed, take it as soon as remembered provided it is at least 8 hours after the previous dose. Do not double up.
Overdose: Symptoms may include severe headache, hypotension, fainting, and rapid heart rate. Seek emergency medical care; treatment is supportive (intravenous fluids, positioning, and, if needed, vasopressors).
Discontinuation: No tapering is required because isosorbide mononitrate does not cause physical dependence. However, abrupt cessation may lead to rebound angina; patients should discuss any change with their clinician.
This article provides educational information about Imdur and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
